Evidence map›Paper›PMID 34310044›Full record

Trial reportAlzheimer's & dementia : the journal of the Alzheimer's Association2022

Mediterranean and Western diet effects on Alzheimer's disease biomarkers, cerebral perfusion, and cognition in mid-life: A randomized trial.

Siobhan Hoscheidt, Ashley H Sanderlin, Laura D Baker, Youngkyoo Jung, Samuel Lockhart, Derek Kellar, Christopher T Whitlow, Angela J Hanson, Seth Friedman, Thomas Register and 2 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 91 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
91citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

91 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. The Effects of Pomegranate Seed Oil on Mild Cognitive Impairment.Journal of Alzheimer's disease : JAD · 2024
    Trial
  7. Trial
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Lipid metabolism, microglia, and stroke.Neural regeneration research · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article

31 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Siobhan HoscheidtWake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Ashley H SanderlinWake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Laura D BakerWake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Youngkyoo JungUniversity of California-Davis, Sacramento, California, USA.
Samuel LockhartWake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Derek KellarWake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Christopher T WhitlowWake Forest School of Medicine, Winston-Salem, North Carolina, USA.
Angela J HansonUniversity of Washington Medical Center, Seattle, Washington, USA.
Seth FriedmanSeattle Children's Hospital, Seattle, Washington, USA.
Thomas RegisterWake Forest School of Medicine, Winston-Salem, North Carolina, USA.
James B LeverenzCleveland Clinic Lou Ruovo Center for Brain Health, Cleveland, Ohio, USA.
Suzanne CraftWake Forest School of Medicine, Winston-Salem, North Carolina, USA.

Funding

Wake Forest University School of Medicine Alzheimer's Disease Research CenterP30AG072947 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SUZANNE CRAFT · 2021 to 2026
$24.3M
Udall Center Director's meeting poster awardP50NS062684 · NINDS · UNIVERSITY OF WASHINGTON · PI MONTINE, THOMAS J · 2009 to 2020
$18.3M
Wake Forest Alzheimer's Disease Core CenterP30AG049638 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI RAPP, STEPHEN R · 2016 to 2020
$12.2M
Glucose Regulation and Memory in Alzheimer's DiseaseR37AG010880 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI CRAFT, SUZANNE · 2005 to 2014
$5.2M
Translational Training in Aging and Alzheimer’s Disease Related DisordersT32AG033534 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI STEPHEN B. KRITCHEVSKY · 2009 to 2026
$3.6M
NIA NIH HHS L30 AG074138NIA NIH HHS P30 AG049638NIA NIH HHS P30 AG072947NIA NIH HHS R37 AG010880NIA NIH HHS T32 AG033534NIH HHS R37 AG-10880NINDS NIH HHS P50 NS062684
6 · The paper itself

Abstract

introductionMid-life dietary patterns are associated with Alzheimer's disease (AD) risk, although few controlled trials have been conducted.

methodsEighty-seven participants (age range: 45 to 65) with normal cognition (NC, n = 56) or mild cognitive impairment (MCI, n = 31) received isocaloric diets high or low in saturated fat, glycemic index, and sodium (Western-like/West-diet vs. Mediterranean-like/Med-diet) for 4 weeks. Diet effects on cerebrospinal fluid (CSF) biomarkers, cognition, and cerebral perfusion were assessed to determine whether responses differed by cognitive status.

resultsCSF amyloid beta (Aβ) DISCUSSION: Diet response during middle age may highlight early pathophysiological processes that increase AD risk.

Indexed as

Alzheimer DiseaseCognitive DysfunctionDiet, MediterraneanDiet, WesternAdultAgedAmyloid beta-PeptidesBiomarkersCerebrovascular CirculationCognitionHumansMiddle AgedPeptide Fragmentstau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAlzheimer's diseasecerebral perfusioncerebrospinal fluid biomarkersdiet intervention

Identifiers

PMID34310044
PMCPMC9207984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.